After years of retreat, Big Pharma is re-entering the mental health space, with major moves like Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics and Johnson & Johnson’s $15 billion purchase of Intra-Cellular Therapies. This renewed focus is driven by scientific advances and the urgent need for better treatments for conditions like schizophrenia and bipolar disorder. Read the article here
